Inhibitor discovery of phospholipases and N-acyltransferases

Zhou, J.

Stellingen

Behorende bij het proefschrift

Inhibitor Discovery of Phospholipases and *N*-acyltransferases

Juan Zhou, Leiden, September 2020

1. The limited structural variety of *N*-Acylethanolamines does not restrict their tremendous activities in biological systems.
   This thesis, ***Chapter 1***.

2. The development of selective protein inhibitors can lag far behind that of the protein research.
   This thesis, ***Chapter 2***.

3. Structure-based drug design is not the only means to arrive at good inhibitors for a protein.
   This thesis, ***Chapter 3***.

4. Though activity-based protein profiling itself is a very powerful technology, the profiling of the biological consequence after inhibitors treatment usually requires the application of multiple technologies at the same time.
   This thesis, ***Chapter4***.

5. As the first potent inhibitor for PLAATs, LEI110 paved the way for further research of PLAATs inhibitors.
   This thesis, ***Chapter4***.

6. When the structures of the proteins from the same family are very similar, looking for selective inhibitors for one protein is a combination of experience and fortune.
   This thesis, ***Chapter 5***.

7. To decipher the biological function of a new protein takes much longer than the discovery of the protein itself.
   This thesis, ***Chapter 5***.&*Nat. Chem. Biol.* **2016**, 12 (9), 669-671.

8. The initial discovery of PLAAT as HRAS-like tumor suppressor is not relevant for its new therapeutic role.
   This thesis &*J. Lipid Res.***2011,**52(11),1927-1935

9. Biologists and chemists are like the two wheels of a bike: only when both of them are working together, they can move forwards.

10. Only when a journey comes to an end, will you know how long it takes!